Skip to main content
All lobbying filings

PTC THERAPEUTICS, INC.

Lobbying for PTC THERAPEUTICS, INC.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$170,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New Jersey

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

Innovative payment methodologies for cell and gene therapies Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to the Medicaid Drug Rebate Program Issues related to implementation of Public Law No. 117-169 - The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 946 - The Optimizing Research Progress Hope and New Cures Act and the small molecule penalty, including H.R. 1492 - The Ensuring Pathways to Innovative Cures Act

Issues related to Section 174 R&D Amortization, including H.R. 1990 - American Innovation and R&D Competitiveness Act of 2025 Issues related to the Orphan Drug Tax Credit, including H.R. 1414 - Camerons Law

Issues related to tariffs

Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program Issues related to Public Law No. 119-21 - The One Big Beautiful Bill Act of 2025 Issues related to international reference pricing Issues related to S. 822 and H.R. 1532 - Scientific External Process for Educated Review of Therapeutics Act of 2025

Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria Awareness of Duchenne Muscular Dystrophy

 Bills named in this filing 6
  • S. 822
    Scientific EXPERT Act of 2025
  • H.R. 1532
    Scientific EXPERT Act of 2025
  • H.R. 946
    ORPHAN Cures Act
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • H.R. 1990
    American Innovation and R&D Competitiveness Act of 2025
  • H.R. 1414
    Cameron’s Law

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem